3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
2
Melanoma
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
Imatinib Mesylate
3
Ipilimumab
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
ripretinib
1
pexidartinib
1
pembrolizumab
1
Thalidomide
1
Specimen Handling
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Injections
1
Fentanyl
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Blood Specimen Collection
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
trastuzumab deruxtecan
×
Dermatologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled